A genomic analysis carried out in order to characterize STSs highlighted that somatic copy number alterations (SCNAs) often involve MDM2–P53 and P16–CDK4–RB1 signaling pathways; with regard to oncogenes, MDM2 is, by definition, amplified in 100% of dedifferentiated liposarcomas, and can also be found in other STS subtypes. This evidence concerns the gene TP53 and liposarcoma.